[{"data":1,"prerenderedAt":167},["ShallowReactive",2],{"drug-iloprost":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":23,"regimens":37,"contraindications":59,"warnings":60,"renal":68,"monitoring":69,"interactions":70,"review":71,"examples":74,"atc":75,"iran":77,"usApproval":105,"links":111,"populations":131},"iloprost",1,{"fa":7,"en":8},"ایلوپروست","Iloprost","blood",{"fa":11,"en":12},"مقلد پروستاسیکلین","Prostacyclin mimetic",[14],{"name":15,"market":16},"Aurlumyn","US",[18,19,20,21,22,7],"aurlumyn","ventavis","ilomedin","ونتاویس","ایلومدین",[24],{"id":25,"form":26,"route":27,"label":28,"concentration":29,"markets":32,"refs":33},"vial-100","injection","iv","100 mcg\u002FmL single-dose vial",{"amount":30,"unit":31,"perVolumeMl":5},100,"mcg",[16],[34],{"source":35,"section":36},"fda-aurlumyn","3",[38],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":49,"dose":50,"refs":54},"frost","frostbite",{"fa":42,"en":43},"سرمازدگی شدید بزرگسال (کاهش خطر قطع انگشت) — انفوزیون وریدی ۶ ساعت در روز تا ۸ روز؛ شروع ۰٫۵ نانوگرم\u002Fkg\u002Fدقیقه","Severe frostbite in adults (to reduce digit amputation) — IV infusion 6 h daily for up to 8 days; start 0.5 ng\u002Fkg\u002Fmin",{"minAge":45},{"value":46,"unit":47},18,"year","notCalculated","mg",{"reason":51},{"fa":52,"en":53},"هر ۳۰ دقیقه ۰٫۵ نانوگرم\u002Fkg\u002Fدقیقه افزایش تا حداکثر ۲؛ روز ۲ و ۳ تیتراسیون تکرار؛ از روز ۴ با بالاترین دوز تحمل‌شده. نارسایی متوسط\u002Fشدید کبد: شروع ۰٫۲۵. علائم حیاتی پیش و پس از هر افزایش. شکل استنشاقی (Ventavis) برای PAH جداست.","Increase by 0.5 ng\u002Fkg\u002Fmin every 30 min to max 2; repeat titration on days 2 and 3; from day 4 start at the highest tolerated rate. Moderate\u002Fsevere hepatic impairment: start 0.25. Vital signs before and after each increase. Inhaled Ventavis for PAH is a different product.",[55,57],{"source":35,"section":56},"2.1",{"source":35,"section":58},"2.3",[],[61],{"text":62,"refs":65},{"fa":63,"en":64},"افت فشار علامت‌دار.","Symptomatic hypotension.",[66],{"source":35,"section":67},"5.1",[],[],[],{"status":72,"reviewer":73,"date":73},"unverified",null,[],[76],"B01AC11",{"status":78,"forms":79,"refs":100},"registered",[80,84,88,92,96],{"code":81,"en":82,"fa":83},"16299","ILOPROST 0.05MG\u002F0.5ML AMP","آمپول ایلوپروست ۰٫۰۵ میلی‌گرم \u002F ۰٫۵ میلی‌لیتر",{"code":85,"en":86,"fa":87},"07961","ILOPROST 20MCG\u002F1ML AMP","آمپول ایلوپروست ۲۰ میکروگرم \u002F ۱ میلی‌لیتر",{"code":89,"en":90,"fa":91},"07962","ILOPROST 50MCG\u002F2.5ML AMP","آمپول ایلوپروست ۵۰ میکروگرم \u002F ۲٫۵ میلی‌لیتر",{"code":93,"en":94,"fa":95},"12253","ILOPROST TROMETAMOL 10MG\u002FML 2ML AMP INHALER","فرآورده استنشاقی ایلوپروست ترومتامول ۱۰ میلی‌گرم \u002F میلی‌لیتر ۲ میلی‌لیتر",{"code":97,"en":98,"fa":99},"52334","ILOPROST INJECTION, SOLUTION PARENTERAL 20 ug\u002F1mL 1 mL","محلول تزریقی ایلوپروست ۲۰ میکروگرم \u002F ۱ میلی‌لیتر ۱ میلی‌لیتر",[101],{"source":102,"section":103,"url":104},"darooyab-generic","G-3184\u002FIloprost","https:\u002F\u002Fwww.darooyab.ir\u002FG-3184\u002FIloprost",{"kind":106,"refs":107,"id":110},"NDA",[108],{"source":35,"section":109},"SPL approval \u002F marketing category","NDA217933",[112,115,119,123,126,129],{"kind":113,"url":114,"label":110},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=217933",{"kind":116,"url":117,"label":118},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=34036fc0-6832-d066-e063-6394a90a18a4","FDA Aurlumyn",{"kind":120,"url":121,"label":122},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa625114.html","Iloprost Injection",{"kind":120,"url":124,"label":125},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa612032.html","Iloprost Oral Inhalation",{"kind":127,"url":128,"label":76},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AC11",{"kind":130,"url":104,"label":8},"darooyab",{"pregnancy":132,"lactation":141,"pediatric":150,"geriatric":159},{"level":133,"text":134,"quote":137,"refs":138},"caution",{"fa":135,"en":136},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data with AURLUMYN during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.",[139],{"source":35,"section":140},"8.1",{"level":142,"text":143,"quote":146,"refs":147},"avoid",{"fa":144,"en":145},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions, advise women not to breastfeed during treatment with iloprost [see Warnings and Precautions ( 5 ) and Adverse Reactions ( 6 )] .",[148],{"source":35,"section":149},"8.2",{"level":151,"text":152,"quote":155,"refs":156},"not-established",{"fa":153,"en":154},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and efficacy in pediatric patients have not been established.",[157],{"source":35,"section":158},"8.4",{"level":133,"text":160,"quote":163,"refs":164},{"fa":161,"en":162},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",[165],{"source":35,"section":166},"8.5",1792444403447]